Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives.
Lacosamide has been submitted for regulatory approval in the United States and Europe for the treatment of epilepsy. Previous synthetic methods did not permit the elaboration of the structure-activity relationship (SAR) for the 3-oxy site in lacosamide. We report an expedient five-step stereospecific synthesis for N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide analogs beginning with D-serine methyl ester. The procedure incorporated alkyl (e.g. methyl, primary, secondary, and tertiary) and aryl groups at this position. The SAR for the 3-oxy site showed maximal activity in animal seizure models for small 3-alkoxy substituents.
Morieux
Pierre
P
Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Campus Box 7360, Chapel Hill, NC 27599-7360, USA.
Stables
James P
JP
Kohn
Harold
H
D000081:Acetamides / Q000138:chemical synthesis / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000138:chemical synthesis / Q000494:pharmacology*; D001665:Binding Sites; D000078334:Lacosamide; D008297:Male; D051379:Mice; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D000081:Acetamides; D000927:Anticonvulsants; D000078334:Lacosamide
J Med Chem. 1996 Apr 26;39(9):1907-16
8627614
Bioorg Med Chem. 2001 Oct;9(10):2693-708
11557357
J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
13502156
J Med Chem. 2002 Oct 10;45(21):4762-73
12361404
Cleve Clin Q. 1984 Summer;51(2):293-305
6380818
Neurotherapeutics. 2007 Jan;4(1):145-8
17199030
Epilepsia. 1978 Aug;19(4):393-408
359324
CNS Drug Rev. 2007 Spring;13(1):21-42
17461888